Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.45 USD
Change Today -1.22 / -5.38%
Volume 280.6K
OTIC On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

otonomy inc (OTIC) Snapshot

Open
$22.50
Previous Close
$22.67
Day High
$22.86
Day Low
$20.56
52 Week High
03/11/15 - $41.99
52 Week Low
09/5/14 - $18.26
Market Cap
519.1M
Average Volume 10 Days
236.4K
EPS TTM
$-5.46
Shares Outstanding
24.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OTONOMY INC (OTIC)

Related News

No related news articles were found.

otonomy inc (OTIC) Related Businessweek News

No Related Businessweek News Found

otonomy inc (OTIC) Details

Otonomy, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear in the United States and Canada. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which completed Phase III clinical trials to treat pediatric patients with middle ear effusion or fluid at the time of tympanostomy tube placement surgery. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone that is in a Phase IIb clinical trial for the treatment of patients with Ménière’s disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in preclinical development as a potential treatment for tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

56 Employees
Last Reported Date: 08/12/15
Founded in 2008

otonomy inc (OTIC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $692.7K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $471.7K
Chief Commercial Officer
Total Annual Compensation: $68.5K
Chief Scientific Officer
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2014.

otonomy inc (OTIC) Key Developments

Otonomy, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Otonomy, Inc. reported unaudited earnings results for the Second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $12,641,000 against $9,828,000 a year ago. Net loss attributable to common stockholders was $12,544,000 or $0.52 per basic and diluted share against $10,246,000 or $109.07 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $24,749,000 against $20,384,000 a year ago. Net loss attributable to common stockholders was $24,561,000 or $1.04 per basic and diluted share against $21,080,000 or $237.33 per basic and diluted share a year ago.

Otonomy, Inc. to Report Q2, 2015 Results on Aug 12, 2015

Otonomy, Inc. announced that they will report Q2, 2015 results After-Market on Aug 12, 2015

Otonomy, Inc. Initiates Phase 2 Clinical Trial for AuriPro(TM) in Second Label Expansion Indication

Otonomy, Inc. announced the enrollment of the first patients in a Phase 2 clinical trial evaluating AuriPro(TM) for the treatment of patients with acute otitis externa, also known as swimmer's ear. The study is designed to evaluate the feasibility of administering AuriPro to the ear canal in a physician's office setting. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of December 25, 2015 for Otonomy's New Drug Application (NDA) for AuriPro, a sustained-exposure formulation of the antibiotic ciprofloxacin, as a treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery. The one-month, prospective, multicenter, open-label Phase 2 clinical trial is expected to enroll approximately 75 patients, ages 6 months to 80 years old, in the United States. The trial is designed to characterize safety and procedural factors associated with AuriPro administered in subjects with unilateral otitis externa. Subjects will be randomized to receive a single administration of AuriPro ranging in volume from 0.1 mL to 0.4 mL. AuriPro is a sustained-exposure formulation of the antibiotic ciprofloxacin in development for the treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery. AuriPro has been formulated to provide sustained-exposure of ciprofloxacin so that a single administration provides a full course of treatment. There are approximately one million TTP surgeries performed each year in the United States, and antibiotic ear drops are used in nearly all cases. Despite their routine use, no antibiotic ear drop has received FDA approval for this indication. Moreover, current ear drop products require multi-dose, multi-day regimens for efficacy. Full compliance with these regimens can be challenging, and missed antibiotic doses can compromise efficacy and increase the potential for bacterial resistance. The FDA has assigned a PDUFA action date of December 25, 2015 for the company's New Drug Application (NDA) for AuriPro for the treatment of middle ear effusion in pediatric patients undergoing TTP surgery. If approved within the standard review period, Otonomy anticipates a commercial launch for AuriPro in the United States in the first quarter of 2016. AuriPro is also being evaluated in two Phase 2 clinical trials, the first for pediatric patients with acute otitis media with tympanostomy tubes (AOMT) and the second for patients with otitis externa.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OTIC:US $21.45 USD -1.22

OTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OTIC.
View Industry Companies
 

Industry Analysis

OTIC

Industry Average

Valuation OTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OTONOMY INC, please visit www.otonomy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.